| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Infection and Immunity, January 2007, p. 91-103, Vol. 75, No. 1
0019-9567/07/$08.00+0 doi:10.1128/IAI.00120-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Department of Microbiology and Molecular Genetics, Michigan State University, East Lansing, Michigan 48824
Received 23 January 2006/ Returned for modification 19 April 2006/ Accepted 12 October 2006
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
The study of gene regulators in A. pleuropneumoniae has been limited and has yielded the identification of only two to date. These include HlyX (33, 35), a homologue of the Escherichia coli global regulator FNR, and the ferric uptake regulator protein Fur (27). To elucidate how genes are regulated in response to BCAA limitation, a better understanding of potential regulators in A. pleuropneumoniae is needed.
One mechanism known to regulate genes in response to BCAA limitation is the leucine-responsive regulatory protein (Lrp). Lrp was first identified in E. coli as the positive regulator of ilvI (44, 46), a gene whose protein product is involved in BCAA biosynthesis. Other genes, both activated and repressed by Lrp, have been subsequently identified (reviewed in references 6, 7, 14, 40, and 41). A DNA microarray study by Tani et al. showed Lrp to be involved in the regulation of up to 10% of all E. coli genes either directly or indirectly (54). In general, Lrp positively regulates genes involved in biosynthesis of amino acids and negatively regulates genes involved in catabolism of amino acids in E. coli. However, Lrp has been shown to regulate, either directly or indirectly, genes associated with virulence, such as those for fimbriae in E. coli (21, 24, 57, 65, 66) and the hpmBA hemolysin operon of Proteus mirabilis (17). Recently, Lrp was shown to positively regulate the XhlA hemolysin of Xenorhabdus nematophila (10), which is required for virulence in insects.
Genes either directly or indirectly regulated by Lrp may respond to Lrp differently depending upon availability of BCAAs in the environment. Lrp can be a positive or negative regulator, with leucine antagonizing the effect of Lrp, potentiating the effect of Lrp, or having no effect on Lrp (34, 54). For example, Lrp positively regulates the E. coli ilvI gene in the absence of leucine, but the effect is antagonized in the presence of leucine (46). In contrast, the livJ gene, involved in BCAA transport, is repressed by both Lrp and leucine together, but repression is not achieved by either individually (34).
The presence of Lrp and its role in gene expression in A. pleuropneumoniae have not been investigated. We hypothesized that A. pleuropneumoniae contains an Lrp homologue and that this protein is involved in the regulation of a subset of genes expressed during infection and recently shown to have increased in vitro expression in the absence of BCAAs (59). In this study, we have identified an A. pleuropneumoniae serotype 1 gene with similarity to the lrp gene of E. coli. The A. pleuropneumoniae serotype 1 lrp gene was cloned, sequenced, and expressed in a protein expression vector, and hexahistidine (His6)-tagged protein was purified. We report that A. pleuropneumoniae His6-Lrp binds to two in vivo-induced promoters, the iviI promoter, which has been identified as the promoter for the ilvIH operon, and the iviG promoter, which expresses a transcript antisense to the A. pleuropneumoniae cps1AB capsule biosynthetic genes, as well as to the nqr promoter and to its own lrp promoter. Furthermore, we report the construction and confirmation of an A. pleuropneumoniae lrp mutant and show through complementation assays that A. pleuropneumoniae Lrp regulates expression of ilvI in A. pleuropneumoniae.
| MATERIALS AND METHODS |
|---|
|
|
|---|
0.1.
|
pir)
(53) were cultured in
Luria-Bertani (LB) medium and used for cloning and mating,
respectively. Ampicillin and kanamycin, when required, were added to
100 µg/ml and chloramphenicol was added to 10 µg/ml for
plasmid selection in E. coli. The pIvi plasmids listed in Table 1 were constructed by cloning Sau3A-digested A. pleuropneumoniae serotype 1 genomic DNA fragments into the promoter trap in vivo expression technology (IVET) plasmid pTF86 (19) and were identified as containing promoters that were induced during infection in a swine animal model (19, 30). pTF86 contains promoterless luciferase genes (luxAB), promoterless riboflavin genes (ribBAH), and a unique BamHI cloning site. When a functional promoter is cloned into pTF86 in the proper orientation, both the luciferase and riboflavin genes are expressed when the promoter is active. Expression of the riboflavin genes complements an attenuating mutation in the host A. pleuropneumoniae strain used for in vivo expression studies and restores virulence. Expression of luciferase activity from the promoter:Lux fusions can be used to measure the promoter activity.
Molecular manipulations. Genomic DNA from A. pleuropneumoniae was isolated using a QIAGEN-tip 500 as described by QIAGEN (44a).Plasmid DNA was purified using QIAprep spin columns (QIAGEN). DNA-modifying enzymes were obtained from Roche (Roche Applied Science, Indianapolis, IN) and New England Biolabs (New England Biolabs, Inc., Beverly, MA) and used according to the respective manufacturer's specifications. Electrocompetent AP225 was prepared and electroporated as previously described (20). E. coli XL1-Blue mRF' was electroporated using the same conditions as those for A. pleuropneumoniae.
Luciferase assays. For quantitative measurement of luciferase activity, a Turner model 20e luminometer (Turner Designs, Sunnyvale, CA) was utilized as previously described (19). Briefly, 20 µl of broth culture was added to 20 µl of luciferase substrate and mixed for 10 s. The substrate was made by dissolving 20 mg/ml Essentially Fatty Acid Free bovine serum albumin (BSA) (Sigma) and 1 µl of N-decyl aldehyde in 1 ml of H2O and sonicating the solution. The luminometer was set to a delay of 10 s, an integration of 30 s, and a sensitivity of 39.9%. The luminometer relative light unit (RLU) readings were normalized to the OD520 units of the culture.
Induction, purification, and quantification of A. pleuropneumoniae and E. coli His6-Lrp. The A. pleuropneumoniae lrp gene was amplified by PCR using AP100 genomic DNA, Pfu Turbo DNA polymerase (Stratagene), and A. pleuropneumoniae lrp-specific primers MM379-SalI and MM430-BamHI and ligated in frame into pQE30 (QIAGEN) to generate pTW313.
E. coli XL1-Blue mRF'/pTW313 and XL1-Blue mRF'/pCV294, the E. coli His6-Lrp protein expression vector, were grown in LB medium at 35°C and 150 rpm for 4.5 h. One millimolar isopropyl-ß-D-thiogalactoside (IPTG) was added to each culture and incubated for an additional 3 h to an OD600 of 0.4, at which time cell pellets were harvested and frozen. Frozen pellets were resuspended in 4 ml ice-cold binding buffer (5 mM imidazole, 0.5 M NaCl, 20 mM Tris-HCl [pH 7.9]). Samples were sonicated for 1 min until not viscous and then centrifuged at 14,000 x g for 20 min at 4°C to remove cellular debris. His-tagged proteins were purified using Novagen His-Bind Quick 900 cartridges (EMD Biosciences, Inc., Madison, WI) according to the manufacturer's instructions. The cartridges were washed with 20 ml of binding buffer and 10 ml of wash buffer (60 mM imidazole, 0.5 M NaCl, 20 mM Tris-HCl [pH 7.9]) and eluted with 4 ml of elution buffer (1 M imidazole, 0.5 M NaCl, 20 mM Tris-HCl [pH 7.9]). Eluted proteins were dialyzed into 20 mM Tris-HCl (pH 8.0)-0.2 mM EDTA-0.2 mM dithiothreitol-0.4 M NaCl by using a Centricon 10 (Millipore Co., Bedford, MA), and an equal volume of 100% ultrapure glycerol was added to each sample. Bio-Rad protein microassays were performed using BSA as a standard to determine final protein concentrations. The purified E. coli His6-Lrp and A. pleuropneumoniae His6-Lrp protein samples were stored at 80°C until use.
SDS-PAGE. Protein samples were resuspended in an equal volume of 2x sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer (125 mM Tris-HCl [pH 6.8], 25% glycerol, 2.5% SDS, 2.5% ß-mercaptoethanol, 1.25% bromophenol blue) and loaded on a 12% polyacrylamide gel, as described by Laemmli (31). Gels were stained with Coomassie blue (22).
EMSA. A. pleuropneumoniae DNA fragments for electrophoretic gel mobility shift assays (EMSA) were isolated by PCR using AP100 genomic DNA and gene-specific primers, or vector-specific primers in the case of ivi fragments. The 623-bp genomic fragment in pIviI was cloned into pUC19 to generate the iviI PCR template, pTW286. Primers specific to the pUC19 vector, MM531 and MM532, were used in this case to generate the iviI fragment. For all other ivi fragments, primers specific to pTF86, MM478-lux and MM533-T4, were used.
For an internal control, an E. coli ilvIH promoter
DNA fragment was PCR amplified from pTW328 by using primers
MM478-lux and MM533-T4. To generate pTW328, the ilvIH
promoter was PCR amplified from a colony of CV975 by using primers
MM362-BamHI and MM363-BamHI. The PCR product was digested with BamHI
and ligated to BamHI-digested pUC19 to generate pTW296. The
300-bp BamHI fragment from pTW296 was ligated to
BamHI-digested pTF86 to generate pTW328.
PCR products were gel
extracted and purified using the QIAEX II system (QIAGEN). For
radiolabeling of DNA fragments, 1 pmol of purified DNA fragment was
combined with 10 units T4 polynucleotide kinase (Roche), 50 µCi
[
-32P]ATP (Amersham Biosciences, Piscataway, NJ),
and 1x polynucleotide kinase buffer in a final volume of 20
µl and incubated at 37°C for 1 h. Completed
reactions were inactivated by heating to 68°C for 10 min and
cleaned by centrifuging the reaction volume through a Quick Spin column
for radiolabeled DNA purification (Roche). Purified His6-Lrp
was diluted to 5 ng/µl in binding buffer [20 mM Tris-HCl (pH
8.0), 75 mM NaCl, 5 mM MgCl2, 1 mM dithiothreitol, 12.5%
glycerol, 0.1 mg/ml BSA, 25 µg/ml poly(dI-dC)]. Binding
reaction mixtures containing 0, 5, 30, or 60 ng of His6-Lrp
were incubated with 0.05 pmol of radiolabeled DNA fragment and 0.5
µg poly(dI-dC) brought to a final volume of 20 µl with
binding buffer (8).
Binding reaction mixtures were incubated at room temperature for 20
min, and then reactions were stopped by adding 5 µl of STOP
solution (USB Co., Cleveland, OH). The entire reaction volume was
loaded onto a 5% nondenaturing polyacrylamide gel prepared in
1x Tris-borate-EDTA (pH 8.0) and electrophoresed at 200 V for 2
to 3 h. Gels were dried at 80°C for 40 min and
exposed to Amersham Biosciences Hyperfilm MP film. For quantitative
analysis, gels were scanned on a Storm 860 PhosphorImager (Molecular
Dynamics, Sunnyvale, CA), and images were analyzed using ImageQuant-TL
v2005 software from Amersham Biosciences (Piscataway,
NJ).
Primer extension analysis. Total RNA was isolated from the cell pellets of cultures of AP225/pTW338 and AP225/pKB11 grown in CDMILV to an OD520 of 0.8, using TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. Primer extension analysis was performed as previously described (59) to identify the transcriptional start points for lrp and nqr, using gene-specific primers. Primer extension analysis of the iviI and iviG promoters was previously published (59).
Construction of an A. pleuropneumoniae lrp mutant.
Primers MM459-PstI and MM460-PstI,
both designed with internal PstI restriction sites, were used with an
inverse PCR technique to amplify around the pTW338 construct in
opposite directions. The 4.5-kb linear product from the inverse PCR was
digested with PstI and ligated to itself to generate the reconstituted
plasmid, pTW355. The annealing position of the primers during the
inverse PCR resulted in a
100-bp deletion from the center of
lrp. An 0.9-kb PstI-digested chloramphenicol acetyltransferase
(CAT) resistance cassette, from a PCR using pER187 as the template and
MM489-PstI and MM511-PstI as primers, was ligated to the newly
generated PstI site of pTW355 to generate pTW401. The 3.4-kb
sacR-sacB-nptI BamHI fragment from pUM24Cm
(47) was ligated to
partially BamHI-digested pTW401 to generate pTW402. The sacR
and sacB genes confer sucrose sensitivity in the presence of
sucrose and allow for future selection of double-crossover events. The
nptI gene confers resistance to kanamycin. The SphI/SacI
insert from pTW402 was ligated to similarly digested pGP704
(37) to generate the
knockout construct pTW404. The pTW404 construct was electroporated into
E. coli S17-1(
pir), and this strain was
filter mated with AP225, a nalidixic acid-resistant derivative of
AP100, according to the protocol of Mulks and Buysse
(38). Transconjugants
were isolated on BHI agar supplemented with V factor (BHIV
agar) and containing 2 µg/ml chloramphenicol and 50
µg/ml nalidixic acid after 48 h and screened by PCR
for single- or double-crossover events at the lrp locus. A
single-crossover transconjugant, designated APTW405, was selected and
grown overnight at 35°C and 5% CO2 on BHIV agar
medium supplemented with 2 µg/ml chloramphenicol. The following
day, the single-crossover mutant was inoculated into 1 ml of BHIV
supplemented with 5 µg/ml chloramphenicol and grown at
37°C and 220 rpm for 2 h until slightly turbid. At
this point, 1 ml of BHIV broth medium supplemented with 20% sucrose and
10 µg/ml chloramphenicol was added to the single-crossover
mutant culture to achieve final concentrations of 10% sucrose and 7.5
µg/ml chloramphenicol. This culture was incubated at
37°C and 220 rpm for 5 h to select for
chloramphenicol resistance and sucrose insensitivity. Dilutions of the
chloramphenicol selection/sucrose counterselection culture were plated
on BHIV agar supplemented with 5 µg/ml chloramphenicol and 10%
sucrose and incubated overnight at 35°C and 5% CO2.
This chloramphenicol selection/sucrose counterselection on APTW405
resulted in chloramphenicol-resistant and sucrose-insensitive bacteria
at a density of 6.7 x 107 CFU/ml,
suggesting that the single-crossover event in APTW405 was forced into a
double-crossover event to generate an lrp
mutant.
Southern blot analysis. Chromosomal DNA and plasmid controls were digested with the restriction enzyme EcoRI, and the DNA fragments were separated on an 0.8% ultrapure agarose gel in Tris-acetate-EDTA buffer. Southern blotting was performed as described by Sambrook et al. (50). DNA probes were labeled with digoxigenin (DIG) by using either the PCR DIG probe synthesis or the DIG DNA labeling kit (Roche Applied Science, Indianapolis, IN). Probes included an 0.5-kb lrp PCR fragment, an 0.8-kb CAT cassette fragment, and a 3.7-kb pGP704 (37) fragment. The lrp fragment was generated by PCR using the MM430-BamHI and MM379-SalI primers with AP100 genomic DNA as a template. The CAT cassette fragment was generated by PCR using the MM508 and MM509 primers with pER187 (49) as a template. The pGP704 fragment was generated by digesting the plasmid with BglII. Hybridizations, washes, and developing were performed as described by Fuller et al. (20). Hybridizations were carried out at 42°C for 18 h in 50% formamide, 2% blocking solution (Roche), 5x SSC (1x SSC is 0.15 M NaCl plus 0.015 M sodium citrate), 0.1% Sarkosyl detergent, and 0.02% SDS. Blots were washed three times in 2x SSC-0.1% SDS for 15 min at room temperature and twice in 0.1x SSC-0.1% SDS for 60 min at 68°C. Blots were developed with an alkaline phosphatase-conjugated antidigoxigenin and CDP-Star substrate kit (Roche) according to the manufacturer's instructions.
Complementation induction assays.
The
1.9-kb
SphI/SacI restriction digest fragment from pTW338 was ligated to
similarly digested pGZRS39 to generate the lrp complementation
plasmid, pTW415. Wild-type (AP225/pGZRS39), lrp mutant
(AP359/pGZRS39), and complemented mutant (AP359/pTW415) strains
containing pIviI or pIviG as a second plasmid were grown overnight on
BHIV agar supplemented with 50 µg/ml kanamycin and 50
µg/ml ampicillin for maintenance of both plasmids. The pIviI
and pIviG plasmids contain previously identified
(19) in vivo-induced
promoters fused to luciferase. A sterile cotton-tipped swab was used to
resuspend each bacterial strain in 1.2 ml of CDMILV broth
medium, and 100 µl was used to inoculate 5-ml cultures of
CDM-ILV and CDM+ILV broth medium for each strain.
Cultures were grown at 37°C for 8 h at 220 rpm, with
samples taken every 1 to 2 h and analyzed for luciferase
expression by quantitative luciferase assays. Assays were performed in
triplicate at each time point in each experiment, and experiments were
repeated a minimum of three
times.
Nucleotide sequence accession numbers. A sequence of the A. pleuropneumoniae lrp gene has been deposited in the GenBank database under accession number DQ370064. Sequences of the inserts in the pIvi plasmids used in this study have been previously submitted to GenBank under the following accession numbers: clone iviA, DQ370062; iviG, DQ370063; iviI, DQ370055; iviP, DQ370061; iviS, DQ370056; iviU, DQ370060; iviX, DQ370059; iviY, DQ370058; ivi17b, DQ667682; and ivi17g, DQ370057. Sequence data for the nqr promoter have been submitted to GenBank as an amendment to accession number U24492, which contains the sequence for the A. pleuropneumoniae nqr (previously designated aopA) gene (11).
| RESULTS |
|---|
|
|
|---|
1.9-kb region from A. pleuropneumoniae
serotype 1 into pUC19
(58), which included the
3' end of the upstream rnd gene, the complete
lrp gene, and the 5' end of the downstream
ftsK gene, to generate pTW338. The insert from pTW338 was
sequenced, and the translated lrp sequence from pTW338 was
aligned with Lrp sequences from eight different bacterial species,
including four members of the family Pasteurellaceae, to which
A. pleuropneumoniae belongs (Fig.
1). The translated protein sequence of A. pleuropneumoniae is 71%
identical to that of E. coli Lrp (Fig.
1). The alignment showed
an overall amino acid sequence conservation, including within the
domains for DNA binding, transcriptional activation, and leucine
response identified in Lrp from E. coli
(43) and Pyrococcus
furiosis (32). The
conservation of the domains within A. pleuropneumoniae Lrp
suggests that the domains may have functions similar to those
characterized for E. coli
Lrp.
|
23-kDa protein, as shown by SDS-PAGE.
This was
4.7 kDa larger than the expected size of 18.3 kDa as
predicted from the translated A. pleuropneumoniae lrp gene and
4.2 kDa larger than what has been reported for E.
coli Lrp. The addition of the His6 tag could account
for this difference. Purification of A. pleuropneumoniae (Fig.
2B) and E. coli
His6-Lrp (data not shown) was analyzed by
SDS-PAGE.
|
We then analyzed eight ivi promoter clones that had previously been shown to be induced under BCAA limitation; these were iviG, iviI, iviP, iviS, iviU, iviX, iviY, and ivi17g (Table 1) (59). iviA was used as a negative control because the iviA clone did not respond to limitation of BCAAs (59) and the pIviA insert DNA sequence did not have any similarity to published Lrp consensus binding sites (12, 60). Binding of A. pleuropneumoniae His6-Lrp to the iviG and iviI inserts, but not to the iviA control, was demonstrated by EMSA (Fig. 3A). The presence of A. pleuropneumoniae His6-Lrp retarded the migration of both the 623-bp iviI and the 211-bp iviG fragments in a dose-dependent manner. The presence of two separate retarded bands with the iviI insert suggests that iviI has multiple A. pleuropneumoniae His6-Lrp binding sites. In contrast, A. pleuropneumoniae His6-Lrp did not bind to the iviP, iviS, iviU, iviX, iviY, and ivi17g fragments under these assay conditions (data not shown).
|
To obtain a better understanding of the Lrp regulon of A. pleuropneumoniae, we extended this analysis to include the promoter regions of other genes. The A. pleuropneumoniae putative promoter regions of the Apx toxin genes apxI, apxII, and apxIV; the apf type IV fimbria cluster; the flp-rcp-tad locus for type IV fimbriae, involved in biofilm formation; the ilvG gene, involved in BCAA biosynthesis; the lrp gene; the nqr operon, encoding the Na+-translocating NADH:ubiquinone oxidoreductase; and the serA gene, involved in serine biosynthesis, were isolated by PCR using gene-specific primers (Table 2) and analyzed by EMSA. The migrations of the 778-bp nqr and 751-bp lrp promoter fragments were retarded when A. pleuropneumoniae His6-Lrp was added to the reaction mixture (Fig. 3B). In contrast, A. pleuropneumoniae His6-Lrp was not observed to bind to the apxI, apxII, apxIV, apf, flp-rcp-tad, ilvG, or serA promoter fragments under these assay conditions (data not shown).
|
Identification of transcriptional start sites and analysis of putative promoter regions. Primer extension analysis was used to determine the transcriptional start sites of iviI, iviG, lrp, and nqr. Figure 4 shows the DNA sequences of the regions upstream from the transcriptional start sites for these four promoters. The initiating nucleotide in all four transcriptional start sites identified was predicted to be T. The regions immediately upstream of the transcriptional start sites displayed a conserved 10 region with the sequence TATA(A/T)T as well as a conserved 35 region with the consensus sequence TAGACA, with spacings of 17 to 20 bp between the putative 35 and 10 regions.
|
Construction and confirmation of an A. pleuropneumoniae lrp mutant. To further investigate the role of Lrp in the regulation of ivi genes responding to limitation of BCAAs, an lrp mutant was constructed (Fig. 5). To confirm that the chloramphenicol selection/sucrose counterselection was successful in producing an lrp mutant, 20 potential lrp mutants were screened by PCR using lrp-specific primers MM480 and MM481. Fifteen of the 20 colonies displayed a single 1-kb product that corresponded to a mutant lrp allele. Five colonies displayed both the wild-type 200-bp and mutant 1-kb bands predicted for a single-crossover event (data not shown).
|
A
colony PCR on AP359 using MM480 and MM481 resulted in a 1-kb product,
as predicted for an lrp mutant (Fig.
6B). In comparison, a predicted 200-bp product was observed
for wild-type AP225, and a 1-kb product for E. coli S17-1
(
pir)/pTW404 (Fig.
6B). The PCR screen
supported AP359 as an lrp mutant.
|
Growth of wild-type, lrp mutant, and complemented mutant strains in CDM+ILV and CDMILV. Exponential growth rates of wild-type A. pleuropneumoniae, the lrp mutant, and a complemented mutant constructed by cloning pTW415 into the lrp mutant were compared in both complex and chemically defined growth media (Table 3). Specific growth rates for wild-type and lrp mutant A. pleuropneumoniae were similar in complex media and similar although much lower in complete chemically defined medium. However, while the growth rate for the wild type was further reduced in CDMILV, there was no detectable growth of the lrp mutant in this medium. The ability to grow in CDMILV was restored in the complemented mutant. In addition to an inability to grow in CDMILV, the lrp mutant displayed a slightly longer lag time than wild-type A. pleuropneumoniae in all growth media (data not shown).
|
500 RLU/OD unit in
CDM+ILV in either a wild-type background (AP225/pGZRS39/pIviI),
the lrp mutant background (AP359/pGZRS39/pIviI), or the
complemented mutant background (AP359/pTW415/pIviI), with no
significant increase over the course of the experiment. However,
luciferase activity in the wild-type background increased on average
over 7-fold in CDMILV compared to CDM+ILV in 1 hour
and over 10-fold in 2 hours. In sharp contrast, when the iviI
promoter was placed in an lrp mutant background, no increase
in luciferase activity was observed in CDMILV. In the
complemented mutant, induction of luciferase expression from the
iviI promoter in CDMILV was restored. The apparent
decrease in relative RLU/OD unit in CDMILV compared to
CDM+ILV in the lrp mutant is due to the lack of growth
of the mutant in CDMILV (Table
3). Expression from the
iviI promoter was strongly up-regulated in CDMILV in
the wild-type and complemented mutant strains containing Lrp and was
unresponsive in the Lrp mutant. These data suggest that Lrp is directly
involved in the regulation of the A. pleuropneumoniae ilvIH
promoter within pIviI in response to BCAA limitation.
|
100 RLU/OD unit in
CDM+ILV, that increased two- to threefold within 3 h
in all three backgrounds In the wild-type background, expression from
the iviG promoter was further increased twofold in
CDMILV compared to CDM+ILV (Fig.
7B). This additional
increase in expression from iviG was not seen in the
lrp mutant and was partially restored in the complemented
mutant. Again, the apparent decrease in relative RLU/OD unit in
CDMILV compared to CDM+ILV in the lrp mutant
is due to the lack of growth of the mutant in CDMILV (Table
3). These data suggest
that Lrp is also directly involved in the regulation of the
iviG promoter in response to BCAA limitation, although the
increase in expression for iviG is distinctly lower and slower
than the rapid and robust response seen with
iviI. | DISCUSSION |
|---|
|
|
|---|
However, differences may exist between these similar proteins. A study by Platko and Calvo (43) showed that multiple mutations in Lrp can affect DNA binding, activation, and the leucine response of Lrp. While A. pleuropneumoniae has the same amino acids at 21 of the 22 sites identified as critical for these functions, E. coli has a serine at position 125 of E. coli Lrp whereas A. pleuropneumoniae has an alanine at the homologous position (Fig. 1). The serine was shown to be important in the activation of transcription by Lrp in E. coli. The unconserved alanine in A. pleuropneumoniae Lrp suggests that a difference in regulation could exist between E. coli and A. pleuropneumoniae Lrp. In Haemophilus influenzae, a bacterium closely related to A. pleuropneumoniae, Lrp was shown to affect the expression of fewer proteins (18) than in E. coli (15), which suggests that a difference between the roles of Lrp in E. coli and A. pleuropneumoniae could be expected.
Our main hypothesis guiding this study was that a subset of ivi genes responding similarly to BCAA limitation are also regulated by a similar mechanism. Since Lrp had been identified as a regulator of ilvI in E. coli (44, 46), we speculated that an A. pleuropneumoniae Lrp would regulate not only the A. pleuropneumoniae ivi gene ilvI (19) but also other ivi genes we previously identified as being up-regulated by BCAA limitation (59).
Since it had been previously shown that the E. coli His6-Lrp behaves as the native protein does (36), we began to address our hypothesis by using purified A. pleuropneumoniae His6-Lrp to determine if A. pleuropneumoniae Lrp has a role in the regulation of ivi genes shown to induce under BCAA limitation. The observation that two of the eight identified clone inserts bound A. pleuropneumoniae His6-Lrp supports that a subset of clones shown to induce under BCAA limiting conditions are regulated similarly. The remaining six ivi clone inserts that did not bind A. pleuropneumoniae His6-Lrp could be regulated by countless other mechanisms, such as by other protein regulators or amino acid attenuation, or could be regulated indirectly by Lrp.
The Lrp regulon in E.
coli is extensive, including
10% of all E. coli
genes (54). We identified
A. pleuropneumoniae homologues of several genes known to be
regulated by Lrp in E. coli, including ilvG
(45), serA
(67), and lrp
itself (61), and tested
these by EMSA. Lrp also regulates a variety of virulence-associated
genes, including those for fimbriae in E. coli
(5) and hemolysin in
Xenorhabdus nematophila
(10,
26). Therefore, we also
tested binding of Lrp to the putative A. pleuropneumoniae
promoters of Apx toxin genes, two fimbrial operons, and the
nqr gene. A. pleuropneumoniae Lrp did bind to its own
promoter, suggesting that regulation of the Lrp gene may be similar in
A. pleuropneumoniae and E. coli. However, Lrp failed
to bind to the ilvG or serA promoter, which suggests
that regulation of BCAA biosynthesis by Lrp in A.
pleuropneumoniae is different from, or at least not as complex as,
that in E. coli
(18). A.
pleuropneumoniae Lrp did not bind to the apxI,
apxII, apxIV, apf, or flp-rcp-tad
promoters under the assay conditions used, suggesting that either Lrp
does not regulate these genes in A. pleuropneumoniae, the
effect of Lrp is indirect, or the assay conditions established for
binding to the ilvIH promoter are not optimal for all DNA
fragments. Lrp did bind to the DNA fragment containing the nqr
operon promoter. However, it should be noted that this fragment
potentially also contains the promoter region for a divergently
transcribed upstream open reading frame. A. pleuropneumoniae
nqrA has been shown to be strongly expressed and antigenic in vivo
(11) and has been shown
to be essential for survival during infection
(52). In Vibrio
cholerae, mutations in Nqr affect virulence gene expression
(25). However, there is
no nqr operon in E. coli. This is the first report of
potential regulation of nqr by Lrp. These results indicate
that the A. pleuropneumoniae Lrp regulon, while not as
extensive as that characterized for E. coli, is not limited to
genes involved in BCAA biosynthesis and does include both in
vivo-induced and virulence-associated genes.
While these experiments were not designed to allow accurate calculation of binding affinities of Lrp, we were able to estimate the binding constant for the ilvIH (iviI) promoter to be 125 nM. This estimate is greater than the calculated Kds for E. coli Lrp binding to the E. coli ilvIH gene (8 nM) and to the lrp gene (35 nM) (61) but still within a reasonable range for a DNA-binding protein.
The ability of A. pleuropneumoniae His6-Lrp to bind to the DNA inserts of ivi clones that did not respond to the limitation of BCAAs was not analyzed. Given that certain promoters can be regulated by E. coli Lrp in the presence of leucine and other promoters in the absence of leucine (15, 34, 40), it is distinctly possible that Lrp from A. pleuropneumoniae may bind to additional ivi clone DNA inserts from clones that failed to induce under BCAA limitation. If this is the case, there may be additional ivi genes that are regulated by Lrp that have not been identified within the scope of this study.
While the demonstrated binding of recombinant A. pleuropneumoniae His6-Lrp to DNA fragments in vitro suggests regulation by Lrp, it is not proof that expression of these genes is controlled by Lrp. To complement these data, we analyzed expression from the iviI and iviG promoters in wild-type A. pleuropneumoniae, an lrp mutant, and a complemented mutant. In the presence of leucine, isoleucine, and valine, there was minimal expression from the iviI promoter in all three backgrounds regardless of the presence of Lrp. In the absence of leucine, isoleucine, and valine, expression from the iviI promoter was strongly and rapidly up-regulated in the wild-type and complemented mutant strains containing Lrp but not in the Lrp mutant. These results suggest that the iviI promoter shows Lrp-dependent activation that is antagonized by leucine or by a combination of leucine, isoleucine, and/or valine, with a low basal level of expression in the absence of Lrp, and that Lrp is critical for the regulation of the ilvIH (iviI) in A. pleuropneumoniae.
The role of A. pleuropneumoniae Lrp in the expression of the iviG promoter is less clear. In CDM+ILV, there is an increase in basal activity from this promoter with increased growth (or possibly growth rate) in all three backgrounds, which was not seen with the iviI promoter. In the absence of leucine, isoleucine, and valine, expression from the iviG promoter was up-regulated in the wild-type and complemented mutant strains containing Lrp but not in the Lrp mutant. This pattern of up-regulation in response to BCAA limitation is similar to, but dramatically smaller and less rapid than, the response seen with the iviI promoter. These results suggest that the iviG promoter also shows Lrp-dependent activation that is antagonized by leucine, or by a combination of leucine, isoleucine, and/or valine, but in addition shows expression independent of Lrp. How the Lrp-independent expression of iviG is regulated has not been determined.
Mutation of the lrp gene does not appear to affect the growth rate of A. pleuropneumoniae in complex media or in CDM+ILV, except for a slightly longer lag time in broth cultures. However, the lrp mutant fails to grow in chemically defined medium in the absence of BCAAs. Growth in CDMILV is restored in the complemented mutant, indicating that the lack of growth is due to the mutation in lrp. Determination of whether this lack of growth CDMILV is due solely to the lack of induction of the ilvIH operon in the absence of LRP or to lack of regulation of additional genes involved in BCAA biosynthesis will require more extensive analysis of the Lrp regulon in A. pleuropneumoniae. It should be noted that the lack of growth of the lrp mutant in CDMILV could influence the expression assays. The rapid and robust response to BCAA limitation seen with the iviI promoter strongly suggests that the lack of expression in the lrp mutant strain is due to the lrp mutation and not to lack of growth. The lower and slower response seen with the iviG promoter makes it more difficult to draw this conclusion with complete confidence. However, since A. pleuropneumoniae His6-Lrp binds to the iviG fragment in vitro, the regulation of this promoter by Lrp remains likely.
While the
discovery of A. pleuropneumoniae Lrp binding to and regulating
the expression of the ilvI promoter in A.
pleuropneumoniae is novel because few regulators have been
identified and examined in this organism, we were not surprised since
Lrp had been shown to regulate ilvI in E. coli. In
contrast, the binding of A. pleuropneumoniae Lrp to the
iviG promoter is quite surprising. The pIviG insert contains
the terminal 3' end of the cps1A gene and the terminal
5' end of the cps1B gene of A.
pleuropneumoniae serotype 1, but the promoter in pIviG is in an
antisense orientation to both cps1A and cps1B.
cps1A and cps1B encode putative glycosyl transferases
involved in the synthesis of A. pleuropneumoniae capsular
polysaccharide. Capsule is required for virulence in this respiratory
pathogen. An antisense transcript expressed from the iviG
promoter could affect the expression of cps1B alone, both
cps1A and cps1B, or the entire capsule biosynthetic
operon. While the role of each gene in the biosynthesis of capsule has
not been established, it is known that serotype 1 capsule is composed
of a repeating
N-acetyl-2-dioxy-ß-D-glucopyranosyl and
-D-galactopyranosyl disaccharide that is
partially O acetylated
(2). Two possible roles of
a transcript antisense to the capsule biosynthesis operon could be to
reduce the total amount of capsule or to alter the antigenic structure
by reducing the O acetylation. Reducing the amount of capsule could
serve to expose surface adhesins necessary for attachment to
respiratory epithelial cells. The fact that A.
pleuropneumoniae Lrp binds to this region in vitro and possibly
regulates the expression of the iviG promoter raises the
possibility that Lrp may play a role in regulation of capsule
biosynthesis of A. pleuropneumoniae. Future experiments
comparing the amounts or types of capsule produced in wild-type and the
lrp mutant strains are needed.
In E. coli, Lrp has been implicated in the regulation of genes involved in virulence such as fimbria genes (5), but to our knowledge, this study is the first time that Lrp has been implicated in the regulation of genes specifically induced during infection of the host. Furthermore, it is interesting to speculate on the affect of an lrp mutation on the virulence of A. pleuropneumoniae and compare it to what is known about the global regulator, Fur. Like Lrp, Fur has been shown to be both a positive and negative regulator (23) but can be modulated by iron rather than leucine. A Fur mutant of A. pleuropneumoniae has recently been shown to have reduced virulence (29). An A. pleuropneumoniae lrp mutant may also be attenuated if Lrp is necessary for the correct regulation of genes important in causing disease. Infection trials with the lrp mutant are needed to address this subject.
This is the first report to identify an A. pleuropneumoniae Lrp homologue. While the role of Lrp in the regulation of ilvI in E. coli has been extensively studied, this work addresses the role of A. pleuropneumoniae Lrp in the regulation of A. pleuropneumoniae virulence-associated genes, in vivo-induced genes, and BCAA biosynthetic genes. A. pleuropneumoniae Lrp was shown to bind to the promoter of A. pleuropneumoniae ilvI and regulate the expression under BCAA limitation. Furthermore, Lrp was shown to bind to the putative nqr promoter and the A. pleuropneumoniae serotype 1 capsule biosynthesis operon, suggesting for the first time that Lrp is involved in the regulation of A. pleuropneumoniae serotype 1 capsule biosynthesis and nqr expression. Our results suggest that the Lrp regulon in A. pleuropneumoniae differs from that found in E. coli and is potentially more extensive than the limited regulon found in H. influenzae.
In summary, our previous IVET studies with A. pleuropneumoniae led to the hypothesis that limitation of branched-chain amino acids is an important environmental cue for respiratory pathogens of mammals, which need to survive and multiply in an anatomical location where these amino acids are in short supply. Analysis of the in vivo-induced gene promoters identified in that work demonstrated that 25% of those ivi promoters were up-regulated on chemically defined medium lacking branched-chain amino acids compared to medium containing BCAAs (59). In this study, we have shown that two of these ivi promoters, as well as two additional genes, are regulated by the global regulatory protein Lrp. These results suggest that the ability to synthesize BCAAs, and the ability to produce a functional Lrp protein, may be required for respiratory pathogens of mammals, which further suggests that inhibition of BCAA synthesis or Lrp function might be a fruitful avenue for the development of new classes of antibiotics that would target respiratory pathogens.
| ACKNOWLEDGMENTS |
|---|
We thank Sheng Yang He for use of the pQE30 protein expression vector, Joseph M. Calvo for CV975, Rowena Matthews for pCV294 (used for internal controls), Kristy Bachus for pKB11 (used for analysis of the nqr promoter), and John Nash and the National Research Council of Canada for access to the A. pleuropneumoniae serotype 5 genomic sequence.
| FOOTNOTES |
|---|
Published ahead of print on 23 October 2006. ![]()
| REFERENCES |
|---|
|
|
|---|
| 1. | Abul-Milh,
M., S. E. Paradis, J. D. Dubreuil, and M.
Jacques. 1999. Binding of
Actinobacillus pleuropneumoniae lipopolysaccharides
to glycosphingolipids evaluated by
thin-layer chromatography. Infect. Immun.
67:4983-4987. |
| 2. | Altman, E., J. R. Brisson, and M. B. Perry.1986 . Structural studies of the capsular polysaccharide from Haemophilus pleuropneumoniae serotype 1. Biochem. Cell Biol. 64:707-716.[Medline] |
| 3. | Belanger,
M., D. Dubreuil, J. Harel, C. Girard, and M. Jacques.1990
. Role of lipopolysaccharides in adherence of
Actinobacillus pleuropneumoniae to porcine tracheal rings.Infect. Immun.
58:3523-3530. |
| 4. | Belanger,
M., D. Dubreuil, and M. Jacques. 1994. Proteins found
within porcine respiratory tract secretions bind lipopolysaccharides of
Actinobacillus pleuropneumoniae. Infect. Immun.
62:868-873. |
| 5. | Berthiaume,
F., C. Crost, V. Labrie, C. Martin, E. B. Newman, and J.
Harel. 2004. Influence of L-leucine and
L-alanine on Lrp regulation of foo, coding for
F1651, a Pap homologue. J. Bacteriol.
186:8537-8541. |
| 6. | Brinkman, A. B., T. J. Ettema, W. M. de Vos, and J. van der Oost. 2003. The Lrp family of transcriptional regulators. Mol. Microbiol. 48:287-294.[CrossRef][Medline] |
| 7. | Calvo,
J. M., and R. G. Matthews. 1994.
The leucine-responsive regulatory protein, a global regulator of
metabolism in Escherichia coli. Microbiol. Rev.
58:466-490. |
| 8. | Camacho, E. M., and J. Casadesus. 2002. Conjugal transfer of the virulence plasmid of Salmonella enterica is regulated by the leucine-responsive regulatory protein and DNA adenine methylation. Mol. Microbiol. 44:1589-1598.[CrossRef][Medline] |
| 9. | Chin, N., J. Frey, C. F. Chang, and Y. F. Chang.1996 . Identification of a locus involved in the utilization of iron by Actinobacillus pleuropneumoniae.FEMS Microbiol. Lett. 143:1-6.[CrossRef][Medline] |
| 10. | Cowles, K. N., and H. Goodrich-Blair. 2005. Expression and activity of a Xenorhabdus nematophila haemolysin required for full virulence towards Manduca sexta insects. Cell. Microbiol. 7:209-219.[Medline] |
| 11. | Cruz, W. T., Y. A. Nedialkov, B. J. Thacker, and M. H. Mulks. 1996. Molecular characterization of a common 48-kilodalton outer membrane protein of Actinobacillus pleuropneumoniae. Infect. Immun. 64:83-90.[Abstract] |
| 12. | Cui,
Y., Q. Wang, G. D. Stormo, and J. M. Calvo.1995
. A consensus sequence for binding of Lrp to DNA.J. Bacteriol.
177:4872-4880. |
| 13. | Cullen, J. M., and A. N. Rycroft. 1994. Phagocytosis by pig alveolar macrophages of Actinobacillus pleuropneumoniae serotype 2 mutant strains defective in haemolysin II (ApxII) and pleurotoxin (ApxIII). Microbiology 140:237-244.[Abstract] |
| 14. | D'Ari, R., R. T. Lin, and E. B. Newman.1993 . The leucine-responsive regulatory protein: more than a regulator? Trends Biochem. Sci. 18:260-263.[CrossRef][Medline] |
| 15. | Ernsting,
B. R., M. R. Atkinson, A. J. Ninfa, and
R. G. Matthews. 1992. Characterization of
the regulon controlled by the leucine-responsive regulatory protein in
Escherichia coli. J. Bacteriol.
174:1109-1118. |
| 16. | Fenwick, B., and S. Henry. 1994. Porcine pleuropneumonia.J. Am. Vet. Med. Assoc. 204:1334-1340.[Medline] |
| 17. | Fraser,
G. M., L. Claret, R. Furness, S. Gupta, and C. Hughes.2002
. Swarming-coupled expression of the Proteus
mirabilis hpmBA haemolysin operon. Microbiology
148:2191-2201. |
| 18. | Friedberg,
D., M. Midkiff, and J. M. Calvo. 2001.
Global versus local regulatory roles for Lrp-related proteins:
Haemophilus influenzae as a case study. J.
Bacteriol.
183:4004-4011. |
| 19. | Fuller, T. E., R. J. Shea, B. J. Thacker, and M. H. Mulks. 1999. Identification of in vivo induced genes in Actinobacillus pleuropneumoniae.Microb. Pathog. 27:311-327.[CrossRef][Medline] |
| 20. | Fuller, T. E., B. J. Thacker, and M. H. Mulks. 1996. A riboflavin auxotroph of Actinobacillus pleuropneumoniae is attenuated in swine.Infect. Immun. 64:4659-4664.[Abstract] |
| 21. | Gally,
D. L., T. J. Rucker, and I. C.
Blomfield. 1994. The leucine-responsive regulatory
protein binds to the fim switch to control phase variation of
type 1 fimbrial expression in Escherichia coli K-12. J.
Bacteriol.
176:5665-5672. |
| 22. | Gorg, A., W. Postel, J. Weser, H. W. Schivaragin, and W. M. Boesken. 1985. Horizontal SDS electrophoresis in ultrathin pore-gradient gels for the analysis of urinary proteins.Sci. Tools 32:5-9. |
| 23. | Grifantini,
R., S. Sebastian, E. Frigimelica, M. Draghi, E. Bartolini, A. Muzzi, R.
Rappuoli, G. Grandi, and C. A. Genco. 2003.
Identification of iron-activated and -repressed Fur-dependent genes by
transcriptome analysis of Neisseria meningitidis group B.Proc. Natl. Acad. Sci. USA
100:9542-9547. |
| 24. | Hale, W. B., M. W. van der Woude, B. A. Braaten, and D. A. Low. 1998. Regulation of uropathogenic Escherichia coli adhesin expression by DNA methylation. Mol. Genet. Metab. 65:191-196.[Medline] |
| 25. | Hase,
C. C., and J. J. Mekalanos. 1999.
Effects of changes in membrane sodium flux on virulence gene expression
in Vibrio cholerae. Proc. Natl. Acad. Sci. USA
96:3183-3187. |
| 26. | Heungens, K., C. E. Cowles, and H. Goodrich-Blair.2002 . Identification of Xenorhabdus nematophila genes required for mutualistic colonization of Steinernema carpocapsae nematodes. Mol. Microbiol. 45:1337-1353.[CrossRef][Medline] |
| 27. | Hsu, Y. M., N. Chin, C. F. Chang, and Y. F. Chang. 2003. Cloning and characterization of the Actinobacillus pleuropneumoniae fur gene and its role in regulation of ApxI and AfuABC expression. DNA Seq. 14:169-181.[Medline] |
| 28. | Hunneman, W. A. 1986. Incidence, economic effects, and control of Haemophilus pleuropneumoniae infections in pigs.Vet. Q. 8:83-87.[Medline] |
| 29. | Jacobsen,
I., J. Gerstenberger, A. D. Gruber, J. T. Bosse,
P. R. Langford, I. Hennig-Pauka, J. Meens, and G.
F. Gerlach. 2005. Deletion of the ferric uptake
regulator Fur impairs the in vitro growth and virulence of
Actinobacillus pleuropneumoniae. Infect. Immun.
73:3740-3744. |
| 30. | Kastenmayer, R. J. 2002. Characterization of the genes of Actinobacillus pleuropneumoniae involved in oxidative stress and pathogenesis. Ph.D. thesis. Michigan State University, East Lansing. |
| 31. | Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4.Nature 227:680-685.[CrossRef][Medline] |
| 32. | Leonard, P. M., S. H. Smits, S. E. Sedelnikova, A. B. Brinkman, W. M. de Vos, J. van der Oost, D. W. Rice, and J. B. Rafferty.2001 . Crystal structure of the Lrp-like transcriptional regulator from the archaeon Pyrococcus furiosus. EMBO J. 20:990-997.[CrossRef][Medline] |
| 33. | Lian,
C. J., S. Rosendal, and J. I. MacInnes.1989
. Molecular cloning and characterization of a
hemolysin gene from Actinobacillus (Haemophilus)
pleuropneumoniae. Infect. Immun.
57:3377-3382. |
| 34. | Lin,
R., R. D'Ari, and E. B. Newman. 1992.
placMu insertions in genes of the leucine regulon:
extension of the regulon to genes not regulated by leucine. J
Bacteriol.
174:1948-1955. |
| 35. | MacInnes,
J. I., J. E. Kim, C. J. Lian, and
G. A. Soltes. 1990. Actinobacillus
pleuropneumoniae hlyX gene homology with the fnr gene of
Escherichia coli. J. Bacteriol.
172:4587-4592. |
| 36. | Matthews, R. G., Y. Cui, D. Friedberg, and J. M. Calvo.2000 . Wild-type and hexahistidine-tagged derivatives of leucine-responsive regulatory protein from Escherichia coli.Methods Enzymol. 324:322-329.[Medline] |
| 37. | Miller,
V. L., and J. J. Mekalanos. 1988.
A novel suicide vector and its use in construction of insertion
mutations: osmoregulation of outer membrane proteins and virulence
determinants in Vibrio cholerae requires toxR.J Bacteriol.
170:2575-2583. |
| 38. | Mulks, M. H., and J. M. Buysse. 1995. A targeted mutagenesis system for Actinobacillus pleuropneumoniae. Gene. 165:61-66.[CrossRef][Medline] |